ArticleEuropean thyroid journal2026
Pathologic and radiologic response to neoadjuvant therapy in advanced differentiated thyroid cancer.
Article in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Neoadjuvant therapies for locally advanced differentiated thyroid cancer (DTC) aim to downstage disease and thereby reduce the extent of surgical resection without compromising oncologic results. Understanding the histopathologic changes induced by these therapies and their correlation with radiologic response may refine surgical planning and guide optimal treatment protocols. Objective: To characterize the histopathologic effects of neoadjuvant therapies on locally advanced DTC and evaluate their association with radiologic response and surgical outcomes. Methods: This is a retrospective case series of patients with initially unresectable, locally advanced DTC treated with neoadjuvant therapies, lenvatinib or dabrafenib/trametinib. All patients underwent comprehensive clinical, radiologic, and histopathologic evaluation before and after neoadjuvant therapy. Histopathologic response was assessed on resection specimens using hematoxylin-eosin staining and immunohistochemistry staining for CD3, CD31, and ERG. The primary outcomes were histopathologic response, including tumor fibrosis, tumor necrosis, vascular density, and immune cell infiltration. Secondary outcomes included radiologic response, surgical feasibility, and perioperative morbidity. Results: All nine patients achieved sufficient tumor regression to allow surgical resection. Histopathology demonstrated therapy-induced tumor fibrosis and necrosis as the predominant changes. Lenvatinib-treated tumors exhibited marked vascular remodeling, reduced microvessel density, and prominent lymphocytic infiltration, whereas BRAF-targeted therapy primarily induced tumor fibrosis without similar vascular or immune changes. The neoadjuvant therapy was well tolerated and did not increase surgical morbidity. Conclusion: Neoadjuvant therapy facilitated R0 resection of locally advanced DTC. Lenvatinib induced vascular remodeling and immune infiltration, in contrast to fibrosis primarily seen with dabrafenib/trametinib. These histologic differences may have implications for future therapeutic decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.